SCL

ANALYST NOTE: SCL (Stepan Company) Date: 2026-06-20 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current Price: $53.94 Conservative Entry: — (Not yet actionable; requires confirmed breakout) Aggressive Entry: $51.37 (Pre-breakout / forming entry) Breakout Level: $68.00 (Resistance level to clear for confirmation) Extension: —

Classification: The setup is classified as FORMING.

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None named at this date.

As of June 20, 2026, there is no named macro or secular thesis driving this specific setup. This is a tactical trade driven by the structural quality of the chart pattern combined with the company's operational turnaround narrative. The conviction must be derived strictly from the setup quality (the forming coil structure) and the fundamental evidence of the "Project Catalyst" efficiency plan, rather than a broad industry tailwind. We do not invent a thesis; we judge the name on the strength of the evidence provided in the earnings transcripts and filings relative to the technical structure.

3. Business Overview

Company: Stepan Company (SCL) Industry: Consumer Staples / Specialty Chemicals Business Model: Stepan is a leading merchant producer of surfactants and specialty chemicals. The company operates a diversified portfolio across three primary segments:

• Surfactants (75% of sales): Principal ingredients for consumer and industrial cleaning products (detergents, shampoos, body washes).
• Polymers (22% of sales): Includes polyurethane polyols for rigid foam insulation (construction) and materials for coatings, adhesives, sealants, and elastomers (CASE).
• Specialty Products: Chemicals for food, flavoring, nutritional supplements, and pharmaceuticals.

Operational Context (as of 2026): The company is currently executing "Project Catalyst," a comprehensive operational and efficiency plan announced in February 2026. Key operational milestones recorded as of the April 28, 2026 earnings transcript include:

• Capacity Utilization: Management expects the Pasadena facility to reach approximately 80% utilization on average in 2026, with full utilization targeted for 2027. This is expected to drive supply chain savings.
• Asset Optimization: The company announced the sale of nonproductive assets, specifically land at the Millsdale site, for $30 million. This transaction was entered into on April 24, 2026, and is expected to close in the second half of 2026.
• Restructuring: The Board approved the shutdown of the Fieldsboro, NJ site and the decommissioning of select assets at Millsdale (IL) and Stalybridge (UK) in the first half of 2026. The company recognized $65.4 million in pre-tax business restructuring expenses related to these actions in Q1 2026.
• Savings Target: Management expects the program to deliver approximately $100 million in pretax savings over the next two years, with roughly 60% of these savings expected to be realized in 2026.

Financial Performance (Q1 2026):

• Volume: Organic volume was flat overall but showed double-digit growth in Crop Productivity, Oilfield, Industrial Cleaning, and the Tier 2/Tier 3 customer base. Specialty Products delivered 30% volume growth.
• EBITDA: Adjusted EBITDA for Q1 2026 was $49.6 million, a 14% decline year-over-year from $57.5 million in Q1 2025. This decline was partially attributed to the one-time restructuring charges and softness in Europe, though Polymers delivered an 8% increase in adjusted EBITDA.
• Capital Expenditures: For 2026, management estimates total capital expenditures will range between $105.0 million and $115.0 million.

4. Archetype and Conviction

Archetype: Defensive Operator Rationale: Stepan fits the "Defensive Operator" archetype due to its exposure to essential consumer staples (cleaning products) and its disciplined execution of a cost-reduction program ("Project Catalyst") to protect margins during a period of mixed volume growth. The company is not a high-growth disruptor but a mature industrial player optimizing its balance sheet and operational efficiency.

Conviction Stack:

• Thesis Strength: Moderate. The thesis is tactical and operational, not macro-driven. The "Project Catalyst" plan provides a clear, quantifiable path to margin expansion ($100M savings target).
• Evidence Quality: High. The evidence base is robust, containing specific management guidance on utilization rates, savings realization timing, and asset sale proceeds. The Q1 2026 results confirm the execution of the restructuring plan.
• Structural Quality: Positive. The "Forming" coil structure suggests a consolidation phase is complete, with support established at $49.95. The current price ($53.94) is holding well above the invalidation line, indicating buyer interest at lower levels.
• Setup Readiness: Partial. The setup is not yet confirmed. The 69% historical breakout rate for forming coils is a favorable statistical edge, but the trade remains incomplete until the $68.00 resistance is cleared.
• Rerating Potential: Moderate. The rerating potential is tied to the successful realization of the $100M savings and the full utilization of the Pasadena plant. If the market begins to price in the 2027 full-utilization scenario, the stock could re-rate from a "restructuring" multiple to a "growth/efficiency" multiple.

Valuation Context: While specific P/E or EV/EBITDA multiples are not provided in the evidence block, the narrative of a 14% EBITDA decline in Q1 2026 followed by a projected 60% realization of savings in 2026 suggests a significant earnings inflection point is anticipated for the full year. The market is currently pricing in the transition costs (restructuring expenses) rather than the future benefits.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A significant deviation from the "Project Catalyst" savings targets (e.g., missing the $100M goal or failing to achieve 80% Pasadena utilization).
• Operational: Failure to close the $30M land sale or unexpected delays in the Fieldsboro shutdown.

Strengtheners:

• Technical: A decisive daily close above the $68.00 breakout level, confirming the coil and signaling a new trend.
• Fundamental: Confirmation of the $100M savings target being on track for 2026 in subsequent guidance, or further evidence of volume growth in the Polymers segment (which already showed 8% EBITDA growth).
• Operational: Successful closure of the Millsdale land sale in the second half of 2026 as expected.

Evidence Gaps:

• Full Year Guidance: While Q1 results and 2026 capital expenditure guidance are available, specific full-year 2026 earnings per share (EPS) or revenue guidance is not explicitly detailed in the provided evidence block, only the savings targets.
• Europe Softness: The transcript notes "continued softness in Europe" offsetting North American growth. The duration and depth of this regional weakness are not quantified beyond the Q1 impact.
• Raw Material Costs: While the company notes it has contracts covering most forecasted requirements, the specific impact of raw material price volatility on the 2026 margin profile is not detailed.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: 1) Technical invalidation if price closes below $49.95; 2) Failure to realize projected savings due to execution delays; 3) Continued softness in European markets offsetting North American growth; 4) Restructuring costs exceeding initial estimates. Sizing hint: Position size should reflect the partial readiness of the setup; treat as a pre-breakout allocation with strict stop-loss discipline. Expected path: Management expects Pasadena utilization to rise to 80% in 2026, driving supply chain savings. If the $68 breakout occurs, the setup confirms, and the market may begin pricing in the 2027 full-utilization scenario. Expected horizon: 3 to 6 months for the breakout confirmation or setup invalidation. Failure mode to watch: A daily close below $49.95, which would signal the breakdown of the forming coil structure and the failure of the current support thesis.